Health Care Equipment

Below are the top small-cap medical appliances & equipment stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at China Kanghui Holdings (NYSE: KH) is 39.37%. China Kanghui's revenue for the same period is $53.71 million. The trailing-...

Masimo (NASDAQ: MASI), the inventor of rainbow® Pulse CO-Oximetry™, and SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced it has acquired PHASEIN AB (Stockholm, Sweden), a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas...

Masimo (NASDAQ: MASI) announced today that MWI Veterinary Supply, Inc. (NASDAQ: MWIV), one of the largest national distributors of medical supplies and equipment to veterinarians, will for the first time distribute Masimo products. Masimo's Radical-7® Pulse CO-Oximeter with upgradable rainbow®...

Analysts at Citigroup downgraded Sony (NYSE: SNE) from “buy” to “neutral.” Sony's shares closed at $13.45 yesterday. Sony's trailing-twelve-month ROE is -14.58%. Analysts at William Blair downgraded Bridgepoint Education (NYSE: BPI) from “outperform” to “market perform.” Bridgepoint Education's...

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 59 points to 12,744.00 and S&P 500 index futures rose 5.20 points to 1,354.40. Nasdaq 100 futures gained 11.25 points to 2,617.25. A Peek Into Global Markets European markets were...

MAKO Surgical Corp. (Nasdaq: MAKO), a medical device company that markets its RIO® Robotic Arm Interactive Orthopedic surgical platform, MAKOplasty® joint specific applications, and proprietary RESTORIS® implants that together enable orthopedic surgeons to consistently, reproducibly and precisely...

Masimo (NASDAQ: MASI) announced today a new study in Respiratory Physiology & Neurobiology shows that noninvasive carboxyhemoglobin (SpCO®) and methemoglobin (SpMet®) measurements with Masimo rainbow® Pulse CO-Oximetry™ are accurate and conclude they can be used as an effective first screening...

Masimo (NASDAQ: MASI) announced today a new study in Respiratory Physiology & Neurobiology shows that noninvasive carboxyhemoglobin (SpCO®) and methemoglobin (SpMet®) measurements with Masimo rainbow® Pulse CO-Oximetry™ are accurate and conclude they can be used as an effective first screening...

Masimo (NASDAQ: MASI) announced today that PSS World Medical, Inc., (NASDAQ: PSSI) a leading national distributor of medical supplies and equipment to office-based physicians, will distribute the new Pronto-7™ – a palm-sized handheld device designed for quick and easy noninvasive spot-checking of...

Masimo (NASDAQ: MASI) announced today that it has been awarded a 33-month group purchasing renewal agreement with the Premier Healthcare Alliance, a leading national healthcare group purchasing organization. The new agreement allows Premier members, at their discretion, to take advantage of...

According to a research report published this morning, Goldman Sachs has lowered MAKO Surgical's (NASDAQ: MAKO) PT from $42 to $36. In the report, Goldman Sachs said, "We maintain our Buy rating on MAKO shares following meetings with management and physicians at the Current Concepts in Joint...

According to a research report published this morning, J.P. Morgan lowered MAKO Surgical's (NASDAQ: MAKO) PT from $33 to $28. In the report, J.P. Morgan said, "Following disappointing 1Q12 results, we conducted nine in-depth interviews with orthopedic surgeons who are either part of Mako's...

Masimo (NASDAQ: MASI) announced today a new study published in the May 2012 edition of the British Journal of Anaesthesia demonstrates that Masimo's acoustic respiration rate (RRa™) from rainbow® Acoustic Monitoring provides similar respiration rate accuracy as capnometry for extubated patients.(1...

MAKO Surgical (NASDAQ: MAKO) is trading lowe on the session following its Q1 earnings announcement yesterday. the company reported an EPS of $(0.28) vs $(0.20) estimates and revenues of $19.6 million vs $23.75 million estimates. Maurice R. Ferré, M.D., President and Chief Executive Officer of MAKO...

According to a research report published this morning, J.P. Morgan has lowered MAKO Surgical's (NASDAQ: MAKO) PT from $37 to $33. In the report, J.P. Morgan said, "Mako reported weak 1Q12 results on Monday evening. The company sold six Rio robots during the quarter, compared to Street...